Please ensure Javascript is enabled for purposes of website accessibility

Shares of BioNTech Soar on a Coronavirus Vaccine Announcement

By Maxx Chatsko – Updated Apr 22, 2020 at 11:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech and its partner, Pfizer, will soon begin the first clinical trials of a coronavirus vaccine in Germany.

What happened

Shares of BioNTech (BNTX 2.48%) rose nearly 30% today after the company announced it will soon begin clinical trials of coronavirus vaccine candidates in Germany. The biotech and its development partner, Pfizer (PFE 1.30%), were granted permission from the Paul-Ehrlich-Institut, Germany's medical regulatory body, to proceed with investigational studies. 

The clinical trial will be the first of a coronavirus vaccine candidate to begin in Germany, although BioNTech and Pfizer expect to soon begin trials in the United States and China, too. As of 10:51 a.m. EDT on Wednesday, the pharma stock had settled to a 13.1% gain.

An arrow jumping up shelves on a wall.

Image source: Getty Images.

So what

The German clinical trial will actually test four unique vaccine candidates. BioNTech designed each to trigger the body's production of antibodies thought to protect against the SARS-CoV-2 virus, which appears to attach to certain cells in the human body using high-affinity spike proteins. 

Two of the vaccine candidates target a long genetic sequence of the spike protein found on the surface of SARS-CoV-2 particles, while the other two contain a shorter sequence targeting a specific section of the spike protein. 

The four coronavirus vaccine candidates are based on messenger RNA (mRNA) chemistry, similar to the technology platform of Moderna. The phase 1/2 trial will seek to find the optimal dose in healthy individuals. 

Now what

Today's news signals progress in humanity's race against the coronavirus pandemic, but there's still a long road ahead for BioNTech and Pfizer. It will take time to assess the safety and efficacy of the vaccine candidates. The human body and adaptive immune system can only produce antibodies so quickly. Meanwhile, it will be important to ensure that the vaccine candidates don't trigger antibody-dependent enhancement (ADE), which could make individuals more susceptible to severe infections. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.66 (1.30%) $0.57
BioNTech SE Stock Quote
BioNTech SE
BNTX
$133.53 (2.48%) $3.23
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$122.35 (0.10%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.